相关实验视频
Updated: Jun 12, 2026

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring
Published on: November 13, 2012
临床治疗中的伴侣诊断:当前应用和未来方向
Yuesong Wu1,2, Rou Xue1, Xiangwen Luo1,3
1Clinical Research Center (CRC) Medical Pathology Center (MPC) Cancer Early Detection and Treatment Center (CEDTC) and Translational Medicine Research Center (TMRC) Chongqing University Three Gorges Hospital, Chongqing University Wanzhou District Chongqing China.
伴随诊断 (CDx) 对于精准医学至关重要,通过生物标志物定制治疗. 本综述探讨了CDx的进步,挑战以及未来的整合到AI增强的医疗保健中.
科学领域:
- 生物标志物的发现和验证.
- 精准医学和个性化疗法
- 诊断技术的发展发展发展.
背景情况:
- 伴随诊断 (CDx) 能够根据个体生物标志物概况制定个性化治疗计划,提高治疗效率,并可能降低医疗保健成本.
- 在瘤学中,已建立的模型使用由生物标志物驱动的向疗法 (例如EGFR,HER2,PD-1/PD-L1).
- 快速的技术进步和复杂的抵抗机制对CDx的开发和应用提出了挑战.
研究的目的:
- 综合审查伴侣诊断的不断变化的监管格局.
- 检查CDx在固体瘤和血液恶性瘤中的当前临床应用.
- 探索多样化的方法论平台和CDx开发中的持续障碍.
主要方法:
- 文献综述综合了关于CDx的当前知识.
- 对监管框架和临床应用进行分析.
- 诊断平台的评估,包括NGS,IHC,液体活检和临床检测.
主要成果:
- 伴随性诊断是精准医学不可或缺的一部分,在瘤学中发挥着既定的作用.
- 现有多种平台,从传统的方法如IHC到新兴的液体活检和POC测试.
- 关键的挑战包括瘤异质性,标准化,活检权衡和经济因素.
结论:
- 伴随诊断面临着不断变化的挑战,但对于个性化医学至关重要.
- 药物和诊断的协同发展至关重要.
- 预计未来将整合到人工智能增强的,多经济驱动的医疗保健生态系统中.
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring: Affecting Factors

